Form 4: Verve Therapeutics Executive Granted Stock Options and Restricted Stock Units

Andrew D. Ashe, President, COO, and General Counsel of Verve Therapeutics, was granted stock options and restricted stock units on January 8, 2025.

Summary

• Andrew D. Ashe, an officer at Verve Therapeutics, received stock options for 225,000 shares and 40,000 restricted stock units on January 8, 2025.
• The stock options have an exercise price of $6.01 per share and vest over a period starting January 8, 2026, and continuing monthly until January 8, 2029.
• The restricted stock units vest in three equal annual installments beginning on April 1, 2026, with the remaining installments on April 1, 2027 and April 1, 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Verve Therapeutics' stock price.
• There is a risk that the stock price may not reach a level that makes the options and restricted stock units valuable to the executive.

Future Outlook

The vesting schedule of the stock options and restricted stock units suggests a long-term focus for the executive's compensation.

Industry Context

Stock option and restricted stock unit grants are common practices in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• The vesting schedule for the stock options, with 25% vesting after one year and the remainder vesting monthly over the following three years, is a fairly standard practice in the biotech industry.
• The restricted stock units vesting in three equal annual installments is also a common vesting schedule for executive compensation.
• Companies like CRISPR Therapeutics and Editas Medicine also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, Verve Therapeutics, VERV, equity